Ad is loading...
GENE
Price
$0.77
Change
-$0.00 (-0.00%)
Updated
Oct 16, 04:59 PM (EDT)
VNRX
Price
$0.79
Change
-$0.02 (-2.47%)
Updated
Nov 22, 03:13 PM (EDT)
110 days until earnings call
Ad is loading...

GENE vs VNRX

Header iconGENE vs VNRX Comparison
Open Charts GENE vs VNRXBanner chart's image
Genetic Technologies
Price$0.77
Change-$0.00 (-0.00%)
Volume$201
CapitalizationN/A
VolitionRX
Price$0.79
Change-$0.02 (-2.47%)
Volume$700
CapitalizationN/A
GENE vs VNRX Comparison Chart
Loading...
VNRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
GENE vs. VNRX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GENE is a Sell and VNRX is a Buy.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (GENE: $0.76 vs. VNRX: $0.81)
Brand notoriety: GENE and VNRX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GENE: 88% vs. VNRX: 151%
Market capitalization -- GENE: $10.53M vs. VNRX: $62.13M
GENE [@Medical Specialties] is valued at $10.53M. VNRX’s [@Medical Specialties] market capitalization is $62.13M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GENE’s FA Score shows that 0 FA rating(s) are green whileVNRX’s FA Score has 0 green FA rating(s).

  • GENE’s FA Score: 0 green, 5 red.
  • VNRX’s FA Score: 0 green, 5 red.
According to our system of comparison, VNRX is a better buy in the long-term than GENE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VNRX’s TA Score shows that 6 TA indicator(s) are bullish.

  • VNRX’s TA Score: 6 bullish, 4 bearish.

Price Growth

GENE (@Medical Specialties) experienced а 0.00% price change this week, while VNRX (@Medical Specialties) price change was +12.64% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.22%. For the same industry, the average monthly price growth was +1.01%, and the average quarterly price growth was -2.21%.

Reported Earning Dates

GENE is expected to report earnings on Feb 28, 2024.

VNRX is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Medical Specialties (+3.22% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VNRX($62.1M) has a higher market cap than GENE($10.5M). VNRX YTD gains are higher at: 13.110 vs. GENE (-68.125). GENE has higher annual earnings (EBITDA): -12.07M vs. VNRX (-34.04M). VNRX has more cash in the bank: 20.7M vs. GENE (3.73M). GENE has less debt than VNRX: GENE (382K) vs VNRX (5.86M). GENE has higher revenues than VNRX: GENE (8.49M) vs VNRX (775K).
GENEVNRXGENE / VNRX
Capitalization10.5M62.1M17%
EBITDA-12.07M-34.04M35%
Gain YTD-68.12513.110-520%
P/E RatioN/AN/A-
Revenue8.49M775K1,096%
Total Cash3.73M20.7M18%
Total Debt382K5.86M7%
FUNDAMENTALS RATINGS
GENE vs VNRX: Fundamental Ratings
GENE
VNRX
OUTLOOK RATING
1..100
4714
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8741
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GENE's Valuation (43) in the Biotechnology industry is in the same range as VNRX (55) in the Medical Or Nursing Services industry. This means that GENE’s stock grew similarly to VNRX’s over the last 12 months.

GENE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VNRX (100) in the Medical Or Nursing Services industry. This means that GENE’s stock grew similarly to VNRX’s over the last 12 months.

GENE's SMR Rating (99) in the Biotechnology industry is in the same range as VNRX (100) in the Medical Or Nursing Services industry. This means that GENE’s stock grew similarly to VNRX’s over the last 12 months.

VNRX's Price Growth Rating (41) in the Medical Or Nursing Services industry is somewhat better than the same rating for GENE (87) in the Biotechnology industry. This means that VNRX’s stock grew somewhat faster than GENE’s over the last 12 months.

VNRX's P/E Growth Rating (100) in the Medical Or Nursing Services industry is in the same range as GENE (100) in the Biotechnology industry. This means that VNRX’s stock grew similarly to GENE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
VNRX
RSI
ODDS (%)
Bullish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
VNRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UPWK15.380.41
+2.74%
Upwork
BFAM111.052.69
+2.48%
Bright Horizons Family Solutions
BSX91.501.33
+1.47%
Boston Scientific Corp
LPTH1.50N/A
N/A
LightPath Technologies
ZH3.57-0.08
-2.19%
Zhihu

GENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GENE has been loosely correlated with HSCS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GENE jumps, then HSCS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GENE
1D Price
Change %
GENE100%
N/A
HSCS - GENE
46%
Loosely correlated
-0.76%
RSLS - GENE
45%
Loosely correlated
+10.71%
AXNX - GENE
32%
Poorly correlated
N/A
INSP - GENE
31%
Poorly correlated
+0.77%
STAA - GENE
31%
Poorly correlated
+1.18%
More

VNRX and

Correlation & Price change

A.I.dvisor tells us that VNRX and OCX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VNRX and OCX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNRX
1D Price
Change %
VNRX100%
+0.12%
OCX - VNRX
28%
Poorly correlated
-2.91%
SRDX - VNRX
25%
Poorly correlated
+0.05%
VAPO - VNRX
25%
Poorly correlated
N/A
GENE - VNRX
23%
Poorly correlated
N/A
RMD - VNRX
23%
Poorly correlated
+0.85%
More